mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

(2015) Bruno Vincenzi et al.   PLoS One

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

(2014) Tadaaki Arizumi et al.   JOURNAL OF GASTROENTEROLOGY

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

(2014) M. Ronot et al.   ONCOLOGIST

EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation

(2013) Huzi Li et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

(2013) Josep M. Llovet et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

(2013) Eun Suk Jung et al.   JOURNAL OF HEPATOLOGY

Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma

(2013) Chang Joon Kim et al.   LIVER INTERNATIONAL

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

(2012) H. J. Prajapati et al.   ANNALS OF ONCOLOGY

Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation

(2012) Beom Kyung Kim et al.   EUROPEAN JOURNAL OF CANCER

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

(2011) Julien Edeline et al.   CANCER

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

(2011) Roopinder Gillmore et al.   JOURNAL OF HEPATOLOGY

Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)

(2010) Masatoshi Kudo et al.   HEPATOLOGY RESEARCH

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE